Market Place
Sourcing Support
AASLD: Gilead wants to move the needle for fatty liver therapies
11 Nov 2019 //
FIERCE BIOTECH
Gilead experimental NASH drug fails another study
26 Apr 2019 //
REUTERS
Gilead teams up with Insitro for experimental NASH treatments
17 Apr 2019 //
REUTERS
Pipeline revamp. Forward thrust. What does a decade of deals at Gilead
04 Mar 2019 //
ENDPTS
Gilead Announces Topline Data From Ph 3 Study of Selonsertib in NASH
12 Feb 2019 //
BUSINESSWIRE
Gilead misses key goal in NASH liver disease trial, shares sink
12 Feb 2019 //
REUTERS
What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
24 Jan 2019 //
ENDPTS
Is 2019 The Turnaround Year For Gilead Sciences?
14 Jan 2019 //
SEEKING ALPHA
At JPM, the NASH flood gates start to crack
12 Jan 2019 //
BIOPHARMA DIVE
Gilead stuffs another NASH drug discovery program into a growing portfolio
04 Jan 2019 //
ENDPTS
Is Gilead Poised for a Comeback?
07 Jul 2018 //
BIOSPACE
Jefferies says Gilead JAK inhibitor could drive turnaround
06 Jul 2018 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.